Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 7,084 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Interventions: inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Rebastinib, Paclitaxel, Eribulin Mesylate; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer
Interventions: recombinant interleukin-12; Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Neoplasm
Interventions: epirubicin, cyclophosphamide, docetaxel, trastuzumab; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more

Conditions: Cancer of Breast
Interventions: Rapamycin; Drug
Lead sponsor: LuZhe Sun; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Central Nervous System Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain
Interventions: methotrexate, liposomal cytarabine, quality-of-life assessment, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 13,759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Body Weight Changes, Breast Neoplasms
Interventions: Self-regulation plus activity monitoring, Self-regulation; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
Interventions: Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing; Drug · Diagnostic Test
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions: Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim; Drug · Other · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Soft Tissue Sarcoma, Breast Cancer
Interventions: LUM015; Drug
Lead sponsor: David Kirsch; Other
Eligibility: 18 Years to 74 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HER2-positive Breast Cancer
Interventions: RNA sequencing, Transcriptome analysis, Trastuzumab, Chemotherapy; Other · Drug
Lead sponsor: OmicsWay Corp.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 40 participants
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Walnut, California

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms, Leukemia, Lymphoma, Non-Hodgkin
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 992 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 70
States / cities: Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more

Conditions: Breast Cancer
Interventions: filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, pamidronate disodium, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 4
States / cities: Chicago, Illinois • Hackensack, New Jersey • Cleveland, Ohio + 1 more

Conditions: Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions: Palbociclib + Letrozole or Fulvestrant; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: Breast Cancer
Interventions: Resistance Exercise, Aerobic Exercise, Behavioral Group Counseling; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Breast Cancer Survivor
Interventions: Mindfulness Oriented Recovery Enhancement (MORE), Questionnaires, Supportive Psychotherapy (SG); Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: San Diego, California • Tallahassee, Florida • Basking Ridge, New Jersey + 6 more

Conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Lumpectomy, Mastectomy, Paclitaxel; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 9 more

Conditions: HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
Interventions: Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review; Procedure · Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • The Bronx, New York • Durham, North Carolina

Conditions: Breast Cancer, Melanoma, Thoracic Cancer, Lymphedema of Upper Arm
Interventions: Ipsilateral peripheral IV insertion; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer, Breast, Health Care Utilization
Interventions: Practice Led Intervention; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older
Enrollment: 910 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Search by objective public record fields.

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

Aging Mammary Stem Cells and Breast Cancer Prevention

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Cathepsin Activatable Fluorescent Probe

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients

Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Imaging Study for FdCyd and THU Cancer Treatment

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Exercising Our ABC's (African- American Breast Cancer Survivors)

Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)

Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care